Lymphoma (DLBCL): A Study Comparing the Efficacy & Safety of Polatuzumab Vedotin w/
Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone vs Rituximab-Cyclophosphamide,
Doxorubicin, Vincristine, & Prednisone in Diffuse Large B-Cell Lymphoma (POLARIX)
Research Question:
What are the good and bad effects of polatuzumab vedotin in combination with four
other drugs, rituximab (R) (also known as Rituxan® and MabThera®), cyclophosphamide
(C), doxorubicin (H), and prednisone (P) (when given together, referred to as R-CHP)
compared with vincristine (O) in combination with R-CHP (referred to as R-CHOP) on
you and your lymphoma and which treatment is better?
Basic Study Information
Purpose:
If you decide to participate in this study you will be randomly assigned by a computer
program to one of the following treatment groups: polatuzumab vedotin and R-CHP with
placebo, or R-CHOP with placebo. Since the difference between the treatment groups
is polatuzumab vedotin in one group and vincristine (O) in the other, both groups
will receive a placebo, which is a substance that looks like either polatuzumab vedotin
or vincristine but contains no active medication. Neither you nor your study doctor
may choose the group that you will be in. You will have an equal chance of being placed
in either group. Neither you nor your study doctor will know which treatment you
receive.
Location: Cancer Center
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03274492?term=go39942&rank=1
Study Reference #: ILYM17113
Lead Researcher (Principal Investigator)
Lead Researcher: Patrick Reagan
Study Contact Information
Study Coordinator: Krista French
Phone: (585) 276-5812
Email: Krista_French@URMC.Rochester.edu
Additional Study Details
Learn More About These Conditions
More information about Lymphoma
Trial Not Found
The study you are looking for is not active at this time.
Return to Search